Doximity (DOCS) Q3 2026: AI Tools Reach 300,000 Prescribers as Policy Uncertainty Delays Pharma Spend

2026-02-05 | By EarningsIQ Research

Doximity’s Q3 results highlight surging clinician adoption of its AI suite and robust core network engagement, yet near-term revenue growth is muted as pharma clients delay budget allocations amid policy uncertainty. Management’s confidence in exiting 2026 with double-digit growth is anchored in deferred pharma spend and the anticipated commercialization of AI products. Investors face a transitional year as Doximity leans into AI infrastructure investment and navigates evolving healthcare marketing dynamics.

Summary

• AI Platform Adoption Accelerates: Over 300,000 prescribers used Doximity’s AI tools, signaling rapid clinical traction.
• Pharma Budget Delays Weigh on Near-Term Growth: Most favored nation policy uncertainty led to slower upfront bookings and deferred revenue.
• Commercial AI Product Launch Poised to Unlock New Revenue Streams: Doximity expects to tap innovation and search budgets later in 2026.

Business Overview

Doximity operates a digital platform for U.S. healthcare professionals, providing workflow tools (telehealth, scheduling, digital fax, AI), a newsfeed, and identity solutions. The company monetizes primarily through subscription-based digital marketing and workflow services sold to pharmaceutical and health system clients. Its core segments include physician network engagement, workflow products, and emerging AI-powered clinical tools.

Performance Analysis

Q3 revenue grew 10% year-over-year, exceeding guidance, but management signaled a pronounced deceleration for Q4, reflecting delayed pharma budget releases due to late-signed most favored nation (MFN) agreements with the White House. Adjusted EBITDA margin remained robust at 60%, though gross margin compressed modestly to 91%, primarily from increased AI infrastructure investment as usage scaled rapidly.

Customer concentration remains high, with the top 20 pharma clients representing the fastest-growing cohort and 126 customers now contributing at least $500,000 each, accounting for 84% of total revenue. Net revenue retention was 112% overall and 117% for the top 20, indicating continued upsell success among large clients. However, the annual selling season saw multiple customers deploying a lower percentage of budgets upfront, with some deals delayed to Q4.

• AI Usage Drives Infrastructure Spend: Over 300,000 unique prescribers used DocsGPT, Doximity’s AI suite, in Q3; usage intensity is high, but revenue contribution is not yet material.
• Workflow Engagement Hits Record: 720,000 unique prescribers used workflow tools, marking the largest sequential gain to date.
• Share Repurchase Accelerates: $196.8 million in buybacks completed in Q3, with a new $500 million authorization approved.

Despite strong core engagement and AI adoption, Doximity’s near-term revenue reflects the impact of industry-wide policy uncertainty, with management expecting a slower start but a stronger finish to calendar 2026 as deferred budgets are deployed and new AI products commercialize.

Executive Commentary

Strategic Positioning

1. AI as a Differentiator and Growth Engine

Doximity’s rapid AI adoption—300,000 prescribers in one quarter—positions it as a leading digital platform for clinical AI. The company’s peer check system, leveraging over 10,000 expert reviewers, addresses trust and safety concerns unique to healthcare AI, a critical moat as hospitals and clinicians demand reliability. Management sees AI as a new TAM, especially in paid search, with plans to commercialize later in 2026.

2. Navigating Pharma Policy Volatility

Uncertainty from MFN agreements and delayed pharma budget releases disrupted Doximity’s usual upfront selling season, pushing bookings into Q4 and lowering near-term growth. However, management expects these deferred budgets to unlock in the upsell cycle, supporting a return to double-digit growth by year-end. The company’s high ROI for pharma clients (median 10:1) remains a key selling point in efficiency-driven environments.

3. Workflow Platform Scale and Stickiness

Record engagement across newsfeed and workflow tools, including 720,000 active prescribers and industry-leading telehealth adoption, reinforce Doximity’s status as a must-have platform for clinicians. Integration with hospital systems and unique features like Doximity Dialer’s high call pickup rates deepen switching costs and defend against point-solution competitors.

4. Margin Flexibility Supports Strategic Investment

Industry-leading EBITDA margins (60%) and strong cash flow enable Doximity to invest aggressively in AI infrastructure and peer check programs without jeopardizing profitability. Management has set a 50% EBITDA margin as a floor, signaling willingness to prioritize long-term platform value creation over near-term margin maximization.

5. Commercialization Path for AI

While current AI usage is not monetized, Doximity plans to launch commercial AI products in the back half of 2026, targeting innovation and search budgets. The company’s unique assets—trusted clinician network, workflow integration, and peer-reviewed AI—position it to capture incremental digital marketing spend as pharma clients seek high-ROI, compliant channels.

Key Considerations

This quarter underscores a pivotal transition for Doximity, as the company moves from digital marketing and workflow leadership into AI-enabled clinical decision support, while navigating macro and regulatory headwinds in its core pharma client base.

Key Considerations:

• AI Commercialization Timeline: Revenue from AI tools is excluded from current guidance, but management expects to launch paid offerings later in 2026, creating potential upside if adoption continues.
• Pharma Budget Normalization: Deferred budgets from MFN-driven uncertainty are expected to flow through in the upsell cycle, but timing and magnitude remain partially outside Doximity’s control.
• Sustained Network Effects: With over 85% of U.S. physicians and two-thirds of NPs/PAs on the platform, Doximity’s scale is a formidable barrier to entry for competitors.
• Margin Compression from AI Investment: Gross margin declined as AI usage ramped, but management is confident that unit costs will improve with scale, as seen in telehealth’s evolution.
• Shareholder Returns via Buybacks: Aggressive share repurchases signal confidence in long-term value, even amid stock price volatility tied to perceived AI disruption risk.

Risks

Policy volatility and regulatory changes in pharma marketing create unpredictability in Doximity’s core revenue streams, as evidenced by this year’s delayed budget releases. AI infrastructure costs are rising ahead of revenue, compressing margins in the short term. Competitive pressure from both traditional publishers and new AI entrants remains high, though Doximity’s network and workflow integration provide defense. The pace and success of AI commercialization will be critical to sustaining above-market growth.

Forward Outlook

For Q4 2026, Doximity guided to:

• Revenue of $143–$144 million (4% YoY growth at midpoint)
• Adjusted EBITDA of $63.5–$64.5 million (45% margin)

For full-year 2026, management maintained guidance:

• Revenue of $642.5–$643.5 million (13% YoY growth at midpoint)
• Adjusted EBITDA of $355.5–$356.5 million (55% margin)

Management emphasized several factors supporting a stronger second half:

• Unreleased pharma budgets are expected to be deployed in the upsell season.
• Commercial AI product launches will tap new client budgets for innovation and search.
• AI infrastructure investment will continue, but margin discipline remains a priority.

Takeaways

• AI Adoption Outpaces Monetization: Rapid clinician and hospital uptake of DocsGPT and Scribe tools validate Doximity’s platform approach, but revenue impact is back-end loaded.
• Pharma Policy Uncertainty Is a Temporary Drag: Delayed budget releases from MFN agreements are expected to normalize, positioning Doximity for a stronger exit to 2026.
• Investors Should Watch AI Commercialization and Upsell Cycles: The timing and magnitude of deferred pharma spend and the ramp of paid AI products will determine whether Doximity can reclaim double-digit growth and sustain premium margins.

Conclusion

Doximity’s Q3 2026 results reflect a business in transition—core engagement and network effects remain strong, AI adoption is surging, and deferred pharma budgets set up a potential second-half rebound. The path to monetizing AI and navigating policy-driven volatility will define the company’s ability to outpace the digital health market in 2026 and beyond.

Industry Read-Through

Doximity’s experience this quarter is a microcosm of broader digital health and pharma marketing trends: Policy-driven budget volatility is reshaping the timing and allocation of digital spend, pressuring near-term growth for platforms reliant on upfront bookings. AI adoption is accelerating among clinicians and hospitals, but monetization lags usage as trust, compliance, and workflow integration become table stakes. Vendors with scale, embedded workflow, and peer-reviewed AI capabilities are best positioned to capture incremental innovation and search budgets as pharma clients seek high-ROI, compliant channels. The industry should expect continued margin pressure from infrastructure investment, but also new revenue streams as AI products move from pilot to paid adoption across healthcare.

DOCS Healthcare Digital Health AI Pharma Marketing Workflow Subscription Share Buybacks